Ocugen
Malvern
About Ocugen
Ocugen is a clinical-stage biopharmaceutical company focused on discoverinOcugen Inc is a clinical-stage biopharmaceutical business focused on discovering, developing, and commercializing gene treatments to cure blinding illnesses, as well as developing a COVID-19 vaccine to save lives. The biologic product candidate aims to provide better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy using the breakthrough modifier gene therapy platform.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $314.0M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jan 2026)
- Ticker: nasdaq:OCGN
- Website: ocugen.com
- Phone: (720)859-3549
Industries & Categories
Biopharma, Biotechnology, Health Care
Social Profiles
Canonical: https://fsome.com/organization/ocugen-60771 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.